These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 36347457)

  • 1. Could nucleocapsid be a next-generation COVID-19 vaccine candidate - author's reply.
    Oronsky B; Larson C; Caroen S; Reid TR
    Int J Infect Dis; 2022 Dec; 125():227. PubMed ID: 36347457
    [No Abstract]   [Full Text] [Related]  

  • 2. Nucleocapsid as a next-generation COVID-19 vaccine candidate.
    Oronsky B; Larson C; Caroen S; Hedjran F; Sanchez A; Prokopenko E; Reid T
    Int J Infect Dis; 2022 Sep; 122():529-530. PubMed ID: 35788417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Could nucleocapsid be a next-generation COVID-19 vaccine candidate?
    Saldivar-Espinoza B; Macip G; Pujadas G; Garcia-Vallve S
    Int J Infect Dis; 2022 Dec; 125():231-232. PubMed ID: 36347459
    [No Abstract]   [Full Text] [Related]  

  • 4. Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2.
    Dangi T; Class J; Palacio N; Richner JM; Penaloza MacMaster P
    Cell Rep; 2021 Sep; 36(10):109664. PubMed ID: 34450033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
    Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
    J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2.
    Afkhami S; D'Agostino MR; Zhang A; Stacey HD; Marzok A; Kang A; Singh R; Bavananthasivam J; Ye G; Luo X; Wang F; Ang JC; Zganiacz A; Sankar U; Kazhdan N; Koenig JFE; Phelps A; Gameiro SF; Tang S; Jordana M; Wan Y; Mossman KL; Jeyanathan M; Gillgrass A; Medina MFC; Smaill F; Lichty BD; Miller MS; Xing Z
    Cell; 2022 Mar; 185(5):896-915.e19. PubMed ID: 35180381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reporting of health equity considerations in vaccine trials for COVID-19: author's reply.
    Kou R; Mbuagbaw L
    J Clin Epidemiol; 2024 Jul; 171():111374. PubMed ID: 38697405
    [No Abstract]   [Full Text] [Related]  

  • 8. The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics.
    Wu W; Cheng Y; Zhou H; Sun C; Zhang S
    Virol J; 2023 Jan; 20(1):6. PubMed ID: 36627683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets.
    Oliveira SC; de Magalhães MTQ; Homan EJ
    Front Immunol; 2020; 11():587615. PubMed ID: 33193414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation.
    Bai Z; Cao Y; Liu W; Li J
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34200602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of Humoral and Cellular Immunity by Intradermal Delivery of SARS-CoV-2 Nucleocapsid Protein Using Dissolvable Microneedles.
    Kuwentrai C; Yu J; Zhang BZ; Hu YF; Dou Y; Gong HR; Huang JD; Xu C
    J Immunol Res; 2021; 2021():5531220. PubMed ID: 34056008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Spike-specific, but attenuated Nucleocapsid-specific T cell responses upon SARS-CoV-2 breakthrough versus non-breakthrough infections.
    Ahmed MIM; Diepers P; Janke C; Plank M; Eser TM; Rubio-Acero R; Fuchs A; Baranov O; Castelletti N; Kroidl I; Olbrich L; Bauer B; Wang D; Prelog M; Liese JG; Reinkemeyer C; Hoelscher M; Steininger P; Überla K; Wieser A; Geldmacher C
    Front Immunol; 2022; 13():1026473. PubMed ID: 36582222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
    Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
    mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid Immunoglobulin G.
    Anderson M; Stec M; Gosha A; Mohammad T; Boler M; Tojo Suarez R; Behun D; Landay A; Cloherty G; Moy J
    J Infect Dis; 2022 Nov; 226(11):1934-1942. PubMed ID: 36263799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19.
    Sadat SM; Aghadadeghi MR; Yousefi M; Khodaei A; Sadat Larijani M; Bahramali G
    Mol Biotechnol; 2021 May; 63(5):389-409. PubMed ID: 33625681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dominant CD8
    Taus E; Hofmann C; Ibarrondo FJ; Hausner MA; Fulcher JA; Krogstad P; Ferbas KG; Tobin NH; Rimoin AW; Aldrovandi GM; Yang OO
    Front Immunol; 2022; 13():835830. PubMed ID: 35273611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.
    Hansen CB; Jarlhelt I; Hasselbalch RB; Hamm SR; Fogh K; Pries-Heje MM; Møller DL; Heftdal LD; Pérez-Alós L; Sørensen E; Larsen MAH; Skjoedt MO; Ostrowski SR; Frikke-Schmidt R; Bayarri-Olmos R; Hilsted LM; Bundgaard H; Nielsen SD; Iversen KK; Garred P
    J Intern Med; 2021 Dec; 290(6):1272-1274. PubMed ID: 34237190
    [No Abstract]   [Full Text] [Related]  

  • 18. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-terminally truncated nucleocapsid protein of SARS-CoV-2 as a better serological marker than whole nucleocapsid protein in evaluating the immunogenicity of inactivated SARS-CoV-2.
    Yue L; Cao H; Xie T; Long R; Li H; Yang T; Yan M; Xie Z
    J Med Virol; 2021 Mar; 93(3):1732-1738. PubMed ID: 32965677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response.
    Renaudineau Y; Abravanel F; Izopet J; Bost C; Treiner E; Congy N; Blancher A
    Clin Immunol; 2022 Apr; 237():108979. PubMed ID: 35301104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.